Press Releases

DANBURY, Conn.--(BUSINESS WIRE)-- Praxair, Inc., a wholly-owned subsidiary of Linde plc, (NYSE:LIN; FWB:LIN) has reached an agreement with Phillips 66 (NYSE:PSX) to supply

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced preliminary data from its ongoing Phase 1 dose-escalation study of AB122. The data are being presented today during a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the third quarter ended September 30, 2018 and provided a corporate update. “As our first year as a public company comes to a close, Vaxart’s main focus conti

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due 2023 (the “Notes”) in a private offering (the “Offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Securities Act”). Om

NESS ZIONA, Israel--(BUSINESS WIRE)-- Foresight Autonomous Holdings Ltd. (NASDAQ and TASE: FRSX), an innovator in automotive vision systems, today announced that its QuadSight™ vision system has been named a 2019

SEOUL, South Korea--(BUSINESS WIRE)-- Hyosung (KRX:004800) (Chairman Cho Hyun-Joon) announced on Nov. 9 that it strengthened communication with overseas markets through &

BERLIN--(BUSINESS WIRE)-- It is a luxury for most Chinese people to run a marathon (whether physical or financial) in another country. With the rapid development of Marathon in recent years, more and more runners in China are moving to overseas Marathon, which is a very popular and fashionable sports trend. This press release features multimedia. View the full release here:

SHANGHAI--(BUSINESS WIRE)-- UEFA and Alipay, the world’s leading payment and lifestyle platform, operated by Ant Financial Services Group, are proud to announce a new eight-year global partnership for all UEFA national team football competitions from 2018 to 2026. This press release features multimedia. View the full release here:

SEOUL, South Korea--(BUSINESS WIRE)-- Hyundai Mobis (KRX:012330) is launching its first open innovation center, ‘M.Cube’ in Silicon Valley of the US to

LONDON--(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to sev

TORONTO--(BUSINESS WIRE)-- Halo Labs Inc. ("Halo" or the "Company") (NEO:HALO) is pleased to report dispensary sales of approximately US$1.23 million for October 2018. This is an increase of approximately US$353,000 over September 2018. Approximately US$245,000 of the dispensary sales in October was derived from the Company’s first full month of sales to dispensaries in Nevada.

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences. Wednesday, November 14, 2018, Aurinia will present a company overview at the Jefferies 2018 London Healthcare Conference in London, UK at 10:00am GMT. The presentation will be webcast live and

LOS ANGELES--(BUSINESS WIRE)-- Health Net of California, Inc., a subsidiary of Centene Corporation, has earned four of five stars from the Centers for Medic

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced clinical data from a Phase 1 study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin (AAT) deficiency, will be presented in a late-breaking poster at Th

MIAMI--(BUSINESS WIRE)-- EnviroStar, Inc. (NYSE American: EVI) (“EVI” or the “Company”) reported record results for the first quarter of its fiscal year ending June 30, 2019. The record results reflect the Company’s consistent execution of its buy-and-build growth strategy. Q1 of Fiscal 2019 Highlights (compared to EVI’s results for the first quarter of the